Serban Dan Costa
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137:2981-8.
06.07.2015Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
06.07.2015Int J Cancer 2015; 137:2981-8
Hein Alexander, Ekici Arif B, Hanusch Claus, Huober Jens, Liedtke Cornelia, Mau Christine, Moisse Matthieu, Müller Volkmar, Nekljudova Valentina, Peuteman Gilian, Rack Brigitte, Rübner Matthias, Van Brussel Thomas, Wang Liewei, Weinshilboum Richard M, Loibl Sibylle, Beckmann Matthias W, Kunz Georg, Lambrechts Diether, von Minckwitz Gunter, Häberle Lothar, Eidtmann Holger, Tesch Hans, Untch Michael, Hilfrich Jörn, Schem Christian, Rezai Mahdi, Gerber Bernd, Dan Costa Serban, Blohmer Jens-Uwe, Schwedler Kathrin, Kittel Kornelia, Fehm Tanja, Fasching Peter A
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015-23.
22.03.2010Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2015-23
von Minckwitz Gunter, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, Untch Michael
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024-31.
22.03.2010Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2024-31
Untch Michael, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, von Minckwitz Gunter